Evidence map›Paper›PMID 29498807›Full record

ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2018

Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay.

Justin Pollara, Chiara Orlandi, Charles Beck, R Whitney Edwards, Yi Hu, Shuying Liu, Shixia Wang, Richard A Koup, Thomas N Denny, Shan Lu and 4 more

Open access · hybridAbstract readClinical Trial, Phase I
In one paragraph

Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The antibody response in HIV-1-infected donors.Current opinion in HIV and AIDS · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Justin PollaraDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina.
Chiara OrlandiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
Charles BeckDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina.
R Whitney EdwardsDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina.
Yi HuInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
Shuying LiuDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Shixia WangDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Thomas N DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
Shan LuDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Georgia D TomarasDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina.
Anthony DeVicoInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
George K LewisInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
Guido FerrariDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina.
Duke University · USUniversity of Maryland, Baltimore · USUniversity of Massachusetts Chan Medical School · USNational Institute of Allergy and Infectious Diseases · US

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
Testing of Blood Samples for Immune Response and Vaccine ResearchZIAAI005073 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$23.4M
HIV/SIV Replication In VivoZIAAI005014 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$22.7M
Physical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1M
Project 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GALLO, ROBERT C · 2016 to 2019
$14.4M
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigensK01OD024877 · OD · DUKE UNIVERSITY · PI POLLARA, JUSTIN JOSEPH · 2017 to 2019
$1.0M
NIAID NIH HHS P01 AI120756NIAID NIH HHS P01 AI124912NIAID NIH HHS P30 AI064518NIH HHS K01 OD024877
6 · The paper itself

Abstract

Several different assay methodologies have been described for the evaluation of HIV or SIV-specific antibody-dependent cell-mediated cytotoxicity (ADCC). Commonly used assays measure ADCC by evaluating effector cell functions, or by detecting elimination of target cells. Signaling through Fc receptors, cellular activation, cytotoxic granule exocytosis, or accumulation of cytolytic and immune signaling factors have been used to evaluate ADCC at the level of the effector cells. Alternatively, assays that measure killing or loss of target cells provide a direct assessment of the specific killing activity of antibodies capable of ADCC. Thus, each of these two distinct types of assays provides information on only one of the critical components of an ADCC event; either the effector cells involved, or the resulting effect on the target cell. We have developed a simple modification of our previously described high-throughput ADCC GranToxiLux (GTL) assay that uses area scaling analysis (ASA) to facilitate simultaneous quantification of ADCC activity at the target cell level, and assessment of the contribution of natural killer cells and monocytes to the total observed ADCC activity when whole human peripheral blood mononuclear cells are used as a source of effector cells. The modified analysis method requires no additional reagents and can, therefore, be easily included in prospective studies. Moreover, ASA can also often be applied to pre-existing ADCC-GTL datasets. Thus, incorporation of ASA to the ADCC-GTL assay provides an ancillary assessment of the ability of natural and vaccine-induced antibodies to recruit natural killer cells as well as monocytes against HIV or SIV; or to any other field of research for which this assay is applied. © 2018 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of ISAC.

Indexed as

AntibodiesAntibody-Dependent Cell CytotoxicityCell LineHIV InfectionsHumansKiller Cells, NaturalLeukocytes, MononuclearMonocytesProspective StudiesReceptors, FcVaccinesAntibodiesReceptors, FcVaccinesantibody-dependent cell-mediated cytotoxicityGranToxiLux assayHIVmonocytesnatural killer cellsperipheral blood mononuclear cells

Identifiers

PMID29498807
PMCPMC5969088
OpenAlexW2792654187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.